Evidence map›Paper›PMID 33665489›Full record

ArticleAdvances in radiation oncology

Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer.

Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami and 4 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Advances in radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05704166 (Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05704166 phase2recruitingnot on this map

Pirfenidone Versus Placebo as Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating

TypeinterventionalSponsorFujian Medical University Union HospitalRan2023 to 2026Enrolled214ConditionsAcute Lung Injury, PreventionArmsPirfenidone/Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Interstitial Lung Abnormalities at CT: Subtypes, Clinical Significance, and Associations with Lung Cancer.Radiographics : a review publication of the Radiological Society of North America, Inc
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tairo KashiharaDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Yuko NakayamaDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Kimiteru ItoDepartment of Radiology in National Cancer Center Hospital, Tokyo, Japan.
Yuko KuboDepartment of Radiology in National Cancer Center Hospital, Tokyo, Japan.
Kae OkumaDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Satoshi ShimaDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Satoshi NakamuraDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Kana TakahashiDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Koji InabaDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Naoya MurakamiDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Hiroshi IgakiDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Yuichiro OheDepartment of Thoracic Oncology in National Cancer Center Hospital, Tokyo, Japan.
Masahiko KusumotoDepartment of Radiology in National Cancer Center Hospital, Tokyo, Japan.
Jun ItamiDepartment of Radiotherapy in National Cancer Center Hospital, Tokyo, Japan.
Tokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAdjuvant durvalumab has become a standard treatment after chemoradiation therapy for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Accordingly, predicting radiation pneumonitis (RP) requiring steroidal treatment (steroid-RP) is of utmost importance because steroidal administration is reported to weaken the effectiveness of immunotherapy. However, grade 2 RP was used as an index of RP in previous studies, but it is an ambiguous definition because it includes not only steroid-RP but also a mild cough requiring only a cough medicine. Therefore, in this study, steroid-RP was used for evaluating RP, and the purpose of this study was to investigate predictive factors of steroid-RP, including original simple interstitial lung abnormality scores (ILASs). METHODS AND MATERIALS: A total of 145 patients with LA-NSCLC who received definitive radiation therapy (DRT) in our institution from January 2014 to May 2017 were identified. Original ILASs, performance status, age, respiratory function, Brinkman index, concurrent administration of chemotherapy, and dose-volume histogram metrics of the lung were analyzed to evaluate their association with steroid-RP. Additionally, 3 diagnostic radiologists evaluated the patients' pre-DRT chest computed tomography images and determined the simple ILASs. ILASs were rated as follows: 0: none; 1: abnormality without honeycombing (ground-glass attenuation, fine reticular opacity, and microcysts); and 2: honeycombing.

resultsThe median follow-up period was 729 days. Thirty-one patients (21.4%) experienced steroid-RP. In the univariate analysis, lung V5/V10/VS5, Brinkman index, and ILASs were significant predictive factors of steroid-RP. Additionally, multivariate analysis including Brinkman index ≥840, lung V5 ≥37%, and an ILAS ≥1 revealed that only an ILAS (

conclusionsThe original simple ILAS was an easy-to-use tool and a significant predictive factor of steroid-RP in DRT in patients with LA-NSCLC.

Identifiers

PMID33665489
PMCPMC7897760
OpenAlexW3095391789

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.